Grant✓ Small businesses may apply
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health
- Opportunity #
- PAR-25-225
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.853
- Status
- posted
- Posted
- Nov 4, 2024
- Closes
- Oct 20, 2027
- Funding instrument
- Grant
- Category
- Health
- Cost sharing required
- No
Who can apply
- •Special district governments
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •Private institutions of higher education
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •County governments
- •Small businesses
- •Native American tribal governments (Federally recognized)
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •City or township governments
- •Public and State controlled institutions of higher education
- •Independent school districts
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •For profit organizations other than small businesses
- •State governments
- •Public housing authorities/Indian housing authorities
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.
Contact
National Institutes of Health · grantsinfo@nih.gov